NASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $1.38 -0.11 (-7.38%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.40 +0.02 (+1.45%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiol Therapeutics Stock (NASDAQ:CRDL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiol Therapeutics alerts:Sign Up Key Stats Today's Range$1.37▼$1.4950-Day Range$1.10▼$1.5352-Week Range$0.77▼$2.63Volume795,076 shsAverage Volume367,737 shsMarket Capitalization$114.10 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Read More Cardiol Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCRDL MarketRank™: Cardiol Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 679th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cardiol Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiol Therapeutics are expected to grow in the coming year, from ($0.33) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -4.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -4.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 6.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cardiol Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.19% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Cardiol Therapeutics has recently decreased by 7.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.19% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Cardiol Therapeutics has recently decreased by 7.53%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 9 people have searched for CRDL on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.49% of the stock of Cardiol Therapeutics is held by institutions.Read more about Cardiol Therapeutics' insider trading history. Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDL Stock News HeadlinesCardiol Therapeutics Analyst RatingsJune 4, 2025 | benzinga.comCardiol Therapeutics Analyst RatingsJune 4, 2025 | benzinga.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 2 at 2:00 AM | Porter & Company (Ad)HC Wainwright & Co. Initiates Coverage of Cardiol Therapeutics (CRDL) with Buy RecommendationJune 2, 2025 | msn.comCardiol Therapeutics Reports Q1 2025 Financial ResultsMay 27, 2025 | tipranks.comCardiol Therapeutics Reports Q1 2025 Financial ResultsMay 14, 2025 | tipranks.comCardiol Therapeutics starts phase III trial for heart drugApril 18, 2025 | uk.investing.comRoth MKM Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)April 18, 2025 | markets.businessinsider.comSee More Headlines CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at $1.28 at the start of the year. Since then, CRDL stock has increased by 7.8% and is now trading at $1.38. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) issued its quarterly earnings data on Monday, March, 31st. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Who are Cardiol Therapeutics' major shareholders? Top institutional shareholders of Cardiol Therapeutics include Envestnet Asset Management Inc. (0.22%). How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiol Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings3/31/2025Today8/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDL CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Cardiol Therapeutics$8.00 High Price Target$9.00 Low Price Target$7.00 Potential Upside/Downside+479.7%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-209.63% Return on Assets-141.09% Debt Debt-to-Equity Ratio0.01 Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book6.27Miscellaneous Outstanding Shares82,680,000Free Float78,311,000Market Cap$114.10 million OptionableNot Optionable Beta1.05 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:CRDL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.